The U.S. Federal Trade Commission (FTC) has launched investigations into prominent medical organizations that support gender-affirming care for minors, a move described by a former FTC employee as "very strange." Since July 2025, the agency has reoriented its focus to frame pediatric gender-affirming care as a consumer protection issue, according to a report by WIRED. This development suggests a significant expansion of the FTC's traditional enforcement scope.
In January, the Federal Trade Commission began issuing civil investigative demands (CIDs) to several nonprofit groups. These instruments, similar to subpoenas, compel organizations to provide documents and materials for agency investigations. The American Academy of Pediatrics, the World Professional Association for Transgender Health, and the Endocrine Society all received these demands, as reported by WIRED.
The agency's Bureau of Consumer Protection is spearheading these cases, shifting the commission's operational emphasis. Responding to these CIDs demands substantial resources. Mila Becker, Chief Policy Officer at the Endocrine Society, stated in a declaration supporting a motion to dismiss the CIDs that her organization projects costs exceeding $500,000.
This figure does not include weeks of specialized staff time, she noted. For nonprofit entities, Becker explained, such financial and personnel burdens are not easily absorbed and would significantly strain operational budgets. Furthermore, her organization possesses documents that may contain sensitive patient or health data, requiring extensive anonymization before disclosure.
This shift in regulatory activity coincides with specific personnel changes within the FTC. Glenna Goldis, a former assistant attorney general for New York state, joined the agency around the same time these investigations commenced. She now serves as assistant director for special projects (children and adolescents), according to a recent update to the FTC’s organizational chart.
Goldis has publicly expressed strong views on pediatric gender medicine. In a podcast interview, she stated a desire to "bankrupt" doctors involved in such care, hoping they would lose both their medical and teaching licenses. A spokesperson for the New York Attorney General’s office informed WIRED that Goldis no longer works for their office due to a violation of protocols regarding outside activities.
The agency’s hiring practices also reflect this new direction. Earlier this year, the FTC posted job applications for lawyers whose roles specifically target investigations into gender-affirming care. These postings sought lawyers at the highest levels of the federal pay scale, with a clear mandate to focus on "unfair and deceptive practices impacting children and families, including investigations relating to pediatric gender dysphoria treatment." This targeted recruitment is unusual for the agency.
Traditionally, the FTC’s consumer protection work involved cases against businesses peddling fake health products, such as unproven COVID-19 cures, or nonprofits misusing charitable donations. A former FTC employee, who spoke to WIRED, described the agency’s pivot to target nonprofits in the gender-affirming care space as "really weird." This individual further characterized the practice of hiring lawyers for a specific project, rather than for general skill sets like data protection, as "very unusual." The numbers on the shipping manifest tell the real story here; the specific allocation of resources to this area indicates a deliberate policy choice. FTC Chair Andrew Ferguson signaled his intentions regarding gender-affirming care even before his appointment.
In a document submitted to President Donald Trump's team prior to inauguration, Ferguson outlined plans for the FTC to combat the "trans agenda." His strategy included investigating "doctors, therapists, hospitals, and others who deceptively pushed gender confusion, puberty blockers, hormone replacement, and sex-change surgeries on children and adults while failing to disclose strong evidence that such interventions are not helpful and carry enormous risks." This pre-existing stance now manifests in agency actions. In July 2025, the FTC announced a workshop titled "The Dangers of ‘Gender-Affirming Care’ for Minors." This event clearly indicated the agency’s intent to consider gender-affirming care as a deceptive practice. During the workshop, Ferguson described puberty blockers as a "gateway drug to a lifetime of expensive hormone injections and sex-change surgeries." He also alleged that medical providers had "coaxed" families into allowing gender-affirming care by promising it would be a "fail-safe cure" for their children’s mental health problems.
Studies, however, indicate that access to gender-affirming care reduces depression and suicidality in trans teens. More than 100 FTC staff members signed a statement expressing concern about the workshop, fearing it could lead the agency to pry into confidential doctor-patient consultations. This FTC initiative forms part of a broader administrative effort to target transgender individuals and their access to care.
President Trump signed an executive order shortly after his inauguration titled "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government." This order directly addressed the trans community, stating that "it is the policy of the United States to recognize two sexes, male and female." Trade policy is foreign policy by other means, and here, domestic regulatory policy becomes cultural policy. Other federal agencies have also pursued similar objectives. In July 2025, the Department of Justice subpoenaed doctors and clinics providing gender-related care for minors.
Pam Bondi, then-Attorney General, stated at the time, "Medical professionals and organizations that mutilated children in the service of a warped ideology will be held accountable by this Department of Justice." Later, in December 2025, the Department of Health and Human Services announced a ban on hospitals receiving Medicare and Medicaid funds from performing gender-affirming care. A federal judge overturned this HHS ban earlier this month, writing that "This case highlights a leader’s unserious regard for the rule of law." The legal challenges are mounting. The former FTC employee expressed concern that these cases will create a chilling effect among health care providers. "If the FTC is going to go after nonprofit organizations outside its jurisdiction on these particular issues, then what about any for-profit medical group?" the individual asked, speaking to WIRED.
Medical practitioners might conclude that even mentioning trans health care in their practice is too risky. This could lead to a quiet cessation of such services, effectively reducing access to care. Follow the supply chain of medical services, and you see potential disruption.
Luke Herrine, an assistant professor at the University of Alabama’s school of law specializing in consumer law, suggested that targeting the specific nonprofits could be a goal in itself. "By going after standard setters, it seems like they're trying to say the whole field of trans health care is inherently a deception," Herrine told WIRED. This strategy aims to discredit the foundational medical consensus. However, Herrine also noted that the nonprofits receiving CIDs might not be the ultimate targets.
He suggested that the CIDs could serve as a mechanism to investigate other, for-profit entities. Based on his analysis of the organizations' responses to the CIDs, Herrine believes the agency is trying to "map out where the funding is" and identify the providers themselves. This data collection could inform future enforcement actions.
Why It Matters: These investigations represent a significant redefinition of consumer protection, moving beyond traditional fraud to challenge established medical practices. The financial strain on nonprofits and the potential chilling effect on healthcare providers could restrict access to care for transgender youth nationwide. This shift also illustrates how regulatory bodies can become instruments for broader political and social agendas, impacting not just specific industries but the very fabric of public health services.
It alters the landscape of care. - The FTC has initiated investigations into major medical organizations supporting gender-affirming care for minors. - These probes, utilizing civil investigative demands, impose significant financial and logistical burdens on targeted nonprofits. - The agency’s actions align with broader administrative efforts to restrict access to gender-affirming care. - Legal experts and former FTC staff question the investigations' scope and potential for creating a chilling effect on medical providers. Moving forward, legal challenges to the CIDs are expected to continue. The Endocrine Society’s motion to dismiss the demands will test the legal boundaries of the FTC’s authority in this area.
Observers will also watch for any expansion of these investigations to include for-profit medical groups or individual practitioners. The broader implications for medical consensus and patient access to care will depend on the outcomes of these legal battles and any subsequent policy enactments. Future court rulings will shape the landscape.
Key Takeaways
— - The FTC has initiated investigations into major medical organizations supporting gender-affirming care for minors.
— - These probes, utilizing civil investigative demands, impose significant financial and logistical burdens on targeted nonprofits.
— - The agency’s actions align with broader administrative efforts to restrict access to gender-affirming care.
— - Legal experts and former FTC staff question the investigations' scope and potential for creating a chilling effect on medical providers.
Source: WIRED
